BiotechTube
Home/Esperion Therapeutics (2)/Andrew G. Saik
AG

Andrew G. Saik

Director

Esperion Therapeutics (2)

Therapeutic Areas

Cardiovascular DiseaseMetabolic Disorders

Esperion Therapeutics (2) Pipeline

DrugIndicationPhase
Bempedoic Acid (NEXLETOL)Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)Approved
Bempedoic Acid / Ezetimibe FDC (NEXLIZET)Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)Approved
Bempedoic AcidCardiovascular Risk ReductionRegulatory Review

Leadership Team at Esperion Therapeutics (2)

SK
Sheldon Koenig
President, Chief Executive Officer, Director
MG
Mark Glickman
Senior Vice President, Chief Business Officer
JM
JoAnne M. Foody, M.D., FACC, FAHA
Chief Medical Officer
BH
Benjamin Halladay
Chief Operating Officer and General Counsel
TM
Timothy M. Mayleben
Former President & CEO
JP
John P. Parrish
Chairman of the Board
View full Esperion Therapeutics (2) profile